Iron deficiency anemia (IDA) is the most common cause of anemia worldwide and is usually responsive to oral iron therapy. However, refractory IDA warrants further evaluation to identify underlying causes such as occult blood loss or malabsorption. We report the case of a 29-year-old male who presented with chronic fatigue and exertional dyspnea and was found to have persistent iron deficiency anemia unresponsive to oral iron supplementation. Despite initial management, hemoglobin levels failed to improve, prompting an extensive diagnostic workup. Subsequent investigations revealed occult gastrointestinal blood loss secondary to a small bowel vascular lesion. Targeted intervention led to hematologic recovery. This case highlights the importance of systematic evaluation of refractory iron deficiency anemia and the role of early investigation for occult gastrointestinal pathology.
Iron deficiency anemia (IDA) is a common hematological condition resulting from inadequate iron intake, impaired absorption, or chronic blood loss. In young adults, IDA is frequently attributed to nutritional deficiency, dietary habits, or—in females—menstrual blood loss. However, in males and non-menstruating individuals, the presence of IDA warrants careful evaluation for underlying pathology, particularly chronic gastrointestinal blood loss, even in the absence of overt symptoms [1,2]. Failure to investigate appropriately may result in missed diagnoses of clinically significant conditions.
Refractory iron deficiency anemia, defined as a suboptimal or absent hematologic response to adequate oral iron therapy, represents a distinct clinical challenge. Poor response may result from nonadherence, incorrect dosing, or inadequate duration of therapy, but true refractoriness should prompt further investigation [3]. Important etiologies include malabsorption syndromes such as celiac disease, Helicobacter pylori–associated gastritis, inflammatory bowel disease, autoimmune gastritis, and ongoing occult blood loss from gastrointestinal lesions, including polyps, angiodysplasia, or malignancy [4,5].
Young adults with refractory IDA often present with nonspecific symptoms such as fatigue, reduced exercise tolerance, dyspnea on exertion, and cognitive impairment, which may be mistakenly attributed to lifestyle factors or stress. As a result, diagnosis is frequently delayed, leading to prolonged morbidity and impaired quality of life. A structured, stepwise diagnostic approach incorporating laboratory evaluation, assessment of iron indices, and targeted gastrointestinal investigations is therefore essential.
This case highlights the diagnostic complexity of refractory IDA in a young adult and underscores the importance of maintaining a high index of suspicion for occult gastrointestinal blood loss. Early recognition of refractory disease and timely identification of the underlying cause are critical to instituting definitive management, preventing recurrence, and avoiding long-term complications associated with chronic iron deficiency.
Initial Impression: Chronic anemia, likely iron deficiency, with poor response to oral therapy.
Additional Tests:
Imaging and Endoscopy:
Diagnosis: Refractory iron deficiency anemia due to occult gastrointestinal blood loss.
These were excluded based on laboratory findings, serology, and imaging.
Step 1 – Optimization of Iron Therapy
Step 2 – Definitive Management
Step 3 – Supportive Care
Refractory iron deficiency anemia necessitates a high index of suspicion for ongoing blood loss or malabsorption, particularly in young male patients where nutritional deficiency alone is unlikely [2,4]. Failure to respond to oral iron therapy is a key clinical clue and should prompt early re-evaluation rather than prolonged empirical treatment.
Occult gastrointestinal bleeding remains one of the most important and potentially serious causes of refractory IDA. While upper and lower endoscopy are first-line investigations, lesions within the small bowel may be missed without advanced diagnostic modalities such as capsule endoscopy [5]. Early identification of the bleeding source allows targeted intervention and prevents long-term complications, including repeated transfusions and reduced quality of life.
This case underscores the importance of guideline-driven evaluation and a multidisciplinary approach involving hematology and gastroenterology to achieve optimal outcomes.
This case highlights the diagnostic challenges associated with refractory iron deficiency anemia (IDA) in young adults, particularly in populations where nutritional deficiency is often presumed to be the primary cause. Persistent anemia despite adequate oral iron therapy should raise immediate concern and prompt a systematic evaluation for secondary etiologies, including occult blood loss, malabsorption disorders, and chronic inflammatory conditions. In males and non-menstruating individuals, gastrointestinal sources of blood loss must be carefully excluded, even in the absence of gastrointestinal symptoms or overt bleeding.
Delayed recognition of refractory IDA can result in prolonged morbidity, functional impairment, and reduced quality of life. Chronic iron deficiency is associated not only with fatigue and reduced exercise capacity but also with impaired cognitive function, decreased work productivity, and, in severe cases, cardiovascular strain. Furthermore, failure to identify the underlying cause may allow potentially serious conditions—such as inflammatory bowel disease, peptic ulcer disease, or gastrointestinal malignancy—to progress unchecked. This underscores the importance of moving beyond empirical iron supplementation when treatment response is inadequate.
Early identification and targeted treatment of the underlying pathology are essential to achieving sustained hematologic recovery and preventing recurrence. A structured diagnostic algorithm incorporating detailed history taking, adherence assessment, laboratory evaluation of iron indices, and appropriate endoscopic or radiologic investigations can significantly reduce diagnostic delay. In cases of confirmed malabsorption or ongoing blood loss, timely escalation to parenteral iron therapy and disease-specific management is often required.
A multidisciplinary approach involving primary care physicians, hematologists, gastroenterologists, and dietitians plays a critical role in optimizing outcomes. Such collaboration ensures comprehensive evaluation, individualized treatment planning, and long-term follow-up. Ultimately, increased clinician awareness and adherence to evidence-based diagnostic pathways are key to improving care for young adults with refractory iron deficiency anemia.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Sub-Q Ketamine is Safe and Very Effective for Severe Depression.
2.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
3.
Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.
4.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
5.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation